Inactive Instrument

GW Pharmaceuticals plc

GWPH

US36197T1034

Biotechnology & Medical Research

GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from S&P Global BMI Index

May 10, 2021 at 12:00 am EDT

Latest news about GW Pharmaceuticals plc

Jazz Pharmaceuticals : U.S. FDA approves expanded use of Jazz Pharma's sleep disorder drug Xywav	21-08-12	RE
Sector Update: Health Care Stocks Steady Premarket Tuesday	21-08-10	MT
Jazz Pharmaceuticals : GW Pharmaceuticals Bags UK Nod for New Use of Cannabis-Based Seizure Drug	21-08-10	MT
Jazz Pharmaceuticals' : Subsidiary Gets UK Approval for Epidyolex in Patients With Tuberous Sclerosis Complex-Related Seizures	21-08-10	MT
Gw Pharmaceuticals Receives Approval for Epidyolex (Cannabidiol) from the MHRA for the Treatment of Seizures Associated with Tuberous Sclerosis Complex	21-08-10	CI
Jazz Pharmaceuticals : Updates 2021 Full-Year Guidance Following GW Pharmaceuticals Buy	21-06-17	MT
Jazz Pharmaceuticals : Updates FY2021 Outlook to Reflect GW Pharmaceuticals Purchase	21-06-17	MT
Palla Pharma : Names New CEO; Shares Soar 18%	21-05-26	MT
GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from S&P Global BMI Index	21-05-10	CI
Jazz Pharmaceuticals : Completes Purchase of GW Pharmaceuticals	21-05-05	MT
GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Composite Index	21-05-04	CI
Jazz Pharmaceuticals plc completed the acquisition of GW Pharmaceuticals plc.	21-05-04	CI
GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Biotechnology Index	21-05-03	CI
Gw Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-03	CI
Jazz Pharmaceuticals : Closes $1.5 Billion Notes Offering	21-04-30	MT
GW Pharmaceuticals : Shareholders' Green-light $7.2 Billion Sale To Jazz Pharmaceuticals	21-04-26	MT
GW Pharmaceuticals : Shareholders OK Takeover by Jazz Pharmaceuticals	21-04-23	MT
Jazz Pharmaceuticals : Pharma Prices $1.5 Billion Senior Secured Notes Offering	21-04-22	MT
Jazz Pharmaceuticals : Subsidiary Discloses Proposed Private Offering of Senior Notes	21-04-20	MT
GW Pharmaceuticals plc Receives European Commission Approval for EPIDYOLEX® (Cannabidiol) for the Treatment of Seizures Associated with Tuberous Sclerosis Complex	21-04-20	CI
Insider Trends: 90-Days of Insider Buying at GW Pharmaceuticals Eased Back with Share Disposition	21-04-08	MT
Takeda Pharmaceutical : buys epilepsy treatment rights from Ovid for up to $856 million	21-03-03	RE
GW Pharmaceuticals : Receives Positive Opinion for Epidyolex Application in EU	21-02-26	MT
GW Pharmaceuticals plc Receives Positive CHMP Opinion for Epidyolex (Cannabidiol) for Use as Treatment of Seizures Associated with Tuberous Sclerosis Complex	21-02-26	CI
GW Pharmaceuticals : Reports Wider Q4 Losses, Higher Revenue	21-02-16	MT

GW Pharmaceuticals Ltd is a United Kingdom-based company that operates as a biopharmaceutical company. The Company manufactures pharmaceutical products. The Company specializes in developing, processing, and manufacturing drugs in pharmaceutical preparations for human and veterinary uses. The Company serves customers worldwide.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

GW Pharmaceuticals plc

Equities

GWPH

US36197T1034

Biotechnology & Medical Research

GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from S&P Global BMI Index

Latest news about GW Pharmaceuticals plc

Chart GW Pharmaceuticals plc

Company Profile

Sector Bio Therapeutic Drugs